Pyxis Oncology reveals promising preclinical data for cancer drug

Published 25/04/2025, 18:26
Pyxis Oncology reveals promising preclinical data for cancer drug

BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage biopharmaceutical company with a market capitalization of $67 million, announced robust preclinical data supporting the mechanism of action for its leading drug candidate, micvotabart pelidotin (MICVO), and its continued clinical development. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 7.49, indicating solid short-term financial stability. MICVO is an innovative antibody-drug conjugate (ADC) targeting Extradomain-B Fibronectin (EDB+FN), which is overexpressed in various solid tumor tissues but has low expression in healthy adult tissues.

The preclinical studies demonstrated MICVO’s potential to disrupt tumor structure and induce immunogenic cell death through its unique three-pronged mechanism. In mouse models, MICVO showed broad anti-tumor activity across ten solid tumor indications, with a significant number of models exhibiting strong tumor growth inhibition. Additionally, a combination of MICVO and anti-PD-1 therapy enhanced tumor clearance and immunological memory more effectively than either treatment alone.

These findings were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, held in Chicago, Illinois, on April 28. The data reveal that MICVO might benefit patients as a monotherapy and in combination with anti-PD-1 therapy, particularly for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other advanced solid tumors.

MICVO has received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC. The drug is currently being evaluated in Phase 1 clinical trials as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) for advanced solid tumors. InvestingPro analysis shows the company holds more cash than debt on its balance sheet, providing important runway for these clinical developments.

Pyxis Oncology’s focus remains on developing next-generation therapeutics for challenging cancers, with a goal of providing new treatment options for patients. This press release statement confirms the company’s commitment to advancing its lead candidate based on the strength of the preclinical evidence. With analysts anticipating sales growth and the next earnings report due on May 9, 2025, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.

In other recent news, Pyxis Oncology has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for its investigational drug PYX-201. This designation is aimed at expediting the development and review of drugs that address serious conditions, specifically for adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have not responded to previous treatments. Pyxis Oncology is actively conducting clinical trials for PYX-201, both as a monotherapy and in combination with Merck’s KEYTRUDA® (pembrolizumab). Additionally, Jefferies has adjusted its price target for Pyxis Oncology from $12.00 to $6.00 while maintaining a Buy rating. This adjustment reflects the company’s financial outlook and anticipated data releases from its lead program, MICVO. Jefferies also highlighted Pyxis Oncology’s robust cash position, with $146 million in cash expected to last into the second half of 2026. The firm remains optimistic about the company’s future, despite the competitive landscape and upcoming data events.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.